Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire.
NK alloreactivity
acute myeloid leukemia (AML)
adoptive immunotherapy
donor selection
human leucocyte antigen (HLA)
killer immunoglobulin-like receptors (KIR)
natural killer cells (NK cells)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
11
2022
accepted:
31
01
2023
entrez:
3
3
2023
pubmed:
4
3
2023
medline:
7
3
2023
Statut:
epublish
Résumé
Natural killer (NK) cell-based adoptive immunotherapy in leukemia patients is an emerging field of interest based on clinical evidence of efficacy and safety. Elderly acute myeloid leukemia (AML) patients have been successfully treated with NK cells from HLA-haploidentical donors, especially when high amounts of alloreactive NK cells were infused. The aim of this study was comparing two approaches to define the size of alloreactive NK cells in haploidentical donors for AML patients recruited in two clinical trials with the acronym "NK-AML" (NCT03955848), and "MRD-NK". The standard methodology was based on the frequency of NK cell clones capable of lysing the related patient-derived cells. The alternative approach consisted of the phenotypic identification of freshly derived NK cells expressing, as inhibitory receptors, only the inhibitory KIR(s) specific for the mismatched KIR-Ligand(s) (HLA-C1, HLA-C2, HLA-Bw4). However, in KIR2DS2
Identifiants
pubmed: 36865545
doi: 10.3389/fimmu.2023.1111419
pmc: PMC9971917
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1111419Informations de copyright
Copyright © 2023 Meazza, Ruggeri, Guolo, Minetto, Canevali, Loiacono, Ciardelli, Bo, Luchetti, Serio, Zannoni, Retière, Colomar-Carando, Parisi, Curti, Lemoli and Pende.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as potential conflict of interest.
Références
Blood. 2008 Jul 15;112(2):435-43
pubmed: 18385451
Clin Cancer Res. 2016 Apr 15;22(8):1914-21
pubmed: 26787753
Front Immunol. 2019 May 28;10:1179
pubmed: 31231370
Annu Rev Immunol. 1996;14:619-48
pubmed: 8717527
Front Immunol. 2020 Mar 12;11:429
pubmed: 32226430
Immunity. 1997 Dec;7(6):753-63
pubmed: 9430221
J Immunol. 2013 Sep 1;191(5):2708-16
pubmed: 23918974
Nat Rev Immunol. 2010 Aug;10(8):568-79
pubmed: 20634814
Gene. 2004 Jun 23;335:121-31
pubmed: 15194195
J Exp Med. 1999 Nov 15;190(10):1505-16
pubmed: 10562324
Cancers (Basel). 2020 Aug 05;12(8):
pubmed: 32764469
Eur J Immunol. 1999 May;29(5):1656-66
pubmed: 10359120
Annu Rev Immunol. 2002;20:217-51
pubmed: 11861603
HLA. 2022 Aug;100(2):119-132
pubmed: 35439359
Nat Immunol. 2003 Sep;4(9):913-9
pubmed: 12897781
Blood. 2009 Dec 10;114(25):5182-90
pubmed: 19828694
Front Immunol. 2022 Jan 31;12:804988
pubmed: 35173709
Blood. 2008 Aug 1;112(3):708-10
pubmed: 18502829
Genome Res. 2012 Oct;22(10):1845-54
pubmed: 22948769
Science. 2011 Jan 7;331(6013):44-9
pubmed: 21212348
Nature. 1998 Feb 19;391(6669):795-9
pubmed: 9486650
Blood. 2009 Mar 26;113(13):3119-29
pubmed: 18945967
Immunity. 1999 Nov;11(5):603-13
pubmed: 10591185
Immunol Today. 1990 Jul;11(7):237-44
pubmed: 2201309
Sci Rep. 2016 Mar 31;6:23689
pubmed: 27030405
J Immunol. 2005 Oct 15;175(8):5222-9
pubmed: 16210627
Front Immunol. 2020 Mar 17;11:440
pubmed: 32256494
Front Immunol. 2022 Feb 15;13:821533
pubmed: 35242134
Blood. 2007 Jul 1;110(1):433-40
pubmed: 17371948
Trends Immunol. 2018 Jul;39(7):577-590
pubmed: 29793748
J Clin Med. 2019 Oct 16;8(10):
pubmed: 31623224
J Exp Med. 1997 Dec 1;186(11):1809-18
pubmed: 9382880
HLA. 2022 Aug;100(2):107-118
pubmed: 35411634
J Immunol. 2003 Dec 15;171(12):6640-9
pubmed: 14662867
Science. 2002 Mar 15;295(5562):2097-100
pubmed: 11896281
J Immunol. 2010 Jul 1;185(1):433-41
pubmed: 20525888
Eur J Immunol. 2016 Jun;46(6):1511-7
pubmed: 26990677
Front Immunol. 2021 May 07;12:674778
pubmed: 34025673
Trends Immunol. 2011 Aug;32(8):364-72
pubmed: 21752715
Blood. 1999 Jul 1;94(1):333-9
pubmed: 10381530
Tissue Antigens. 2002 Sep;60(3):254-8
pubmed: 12445308
Blood. 2013 Apr 4;121(14):2678-88
pubmed: 23325834
Immunology. 2009 Oct;128(2):172-84
pubmed: 19740374
Exp Hematol. 2017 Jan;45:10-16
pubmed: 27826123
Immunity. 2017 Nov 21;47(5):820-833
pubmed: 29166586
Front Immunol. 2017 Oct 19;8:1330
pubmed: 29097997
Eur J Immunol. 2013 Apr;43(4):1085-98
pubmed: 23436464
J Immunol. 2008 Mar 15;180(6):3969-79
pubmed: 18322206
Blood. 2019 Mar 28;133(13):1479-1488
pubmed: 30647027
Front Immunol. 2015 Oct 15;6:479
pubmed: 26528283
Nat Rev Immunol. 2005 Mar;5(3):201-14
pubmed: 15719024
PLoS One. 2010 Dec 29;5(12):e15115
pubmed: 21206914
Sci Immunol. 2016 Sep;1(3):
pubmed: 27868107
Blood. 2005 Apr 15;105(8):3051-7
pubmed: 15632206
Int Immunol. 2004 Oct;16(10):1459-66
pubmed: 15314042
Eur J Immunol. 2021 Jul;51(7):1566-1579
pubmed: 33899224
Blood. 2011 Sep 22;118(12):3273-9
pubmed: 21791425
J Immunother Cancer. 2022 Nov;10(11):
pubmed: 36319065
Eur J Immunol. 2009 Sep;39(9):2548-55
pubmed: 19701893